ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 161 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2014. The put-call ratio across all filers is 0.08 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2017 | $21,000 | -97.6% | 550 | -98.2% | 0.01% | -97.5% |
Q2 2017 | $863,000 | -54.3% | 30,947 | -43.7% | 0.36% | -60.4% |
Q1 2017 | $1,889,000 | -0.7% | 54,947 | -16.7% | 0.91% | -5.0% |
Q4 2016 | $1,902,000 | -8.6% | 65,947 | +0.8% | 0.96% | -10.9% |
Q3 2016 | $2,080,000 | -99.9% | 65,397 | -0.3% | 1.07% | +118.7% |
Q2 2016 | $2,129,279,000 | +1284.6% | 65,597 | +1092.7% | 0.49% | +1097.6% |
Q1 2016 | $153,780,000 | -84.7% | 5,500 | -82.1% | 0.04% | -81.0% |
Q1 2015 | $1,003,772,000 | -31.0% | 30,800 | -32.8% | 0.22% | -37.0% |
Q4 2014 | $1,454,150,000 | +28.2% | 45,800 | 0.0% | 0.34% | +58.8% |
Q3 2014 | $1,134,008,000 | +9.6% | 45,800 | 0.0% | 0.22% | +16.8% |
Q2 2014 | $1,034,622,000 | -7.2% | 45,800 | 0.0% | 0.18% | -13.1% |
Q1 2014 | $1,114,314,000 | -2.6% | 45,800 | 0.0% | 0.21% | -8.6% |
Q4 2013 | $1,144,542,000 | -16.7% | 45,800 | -8.4% | 0.23% | -11.4% |
Q3 2013 | $1,373,500,000 | +51.3% | 50,000 | 0.0% | 0.26% | +39.2% |
Q2 2013 | $907,500,000 | – | 50,000 | – | 0.19% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |